A5 Abstracts included age = 49 years, disease duration = 9.5 years, TJC = 24, SJC = 14, HAQ-DI = 1.0, and PASI = 7.9. Forty-four percent of patients were female. Pearson correlation coefficients between variables were -0.6 (HAQ-DI and SF-6D, p < 0.05), -0.2 (PASI and SF-6D, p < 0.05) and 0.1 (HAQ-DI and PASI, p = 0.2) As determined by multiple linear regression, significant independent predictors of PsA-related QoL (in descending order of importance) were: functional loss (HAQ-DI), severity of psoriasis (PASI), and TJC (all p < 0.05). SJC was not a significant predictor of QoL in PsA. CONCLUSIONS: In patients with PsA, the main determinants of QoL measured were degree of diseaserelated functional loss and severity of skin disease. In contrast to findings in rheumatoid arthritis, joint counts were of secondary importance. These findings have important implications for economic evaluations of new treatments for PsA. Information on costs of multiple myeloma (MM) management is scarce. The objective of this incidence-based cost-of-illness study was to assess direct medical costs and cost drivers in major disease phases: primary diagnosis (PD), recurrent (RCD) or refractory disease (RFD). METHODS: A retro projected chart review was performed in 9 centres (n = 176, randomly selected patients) in Belgium (n = 56), France (n = 41), UK (n = 40) and Germany (n = 39). Costs were calculated from the payer's perspective by multiplying resource utilization with local unit costs from official sources. Data collection covered the 2-year period (or up to death) following treatment initiation in 2001. Descriptive statistics were performed on costs. Cost drivers were identified using a linear mixed regression model.
Information on costs of multiple myeloma (MM) management is scarce. The objective of this incidence-based cost-of-illness study was to assess direct medical costs and cost drivers in major disease phases: primary diagnosis (PD), recurrent (RCD) or refractory disease (RFD). METHODS: A retro projected chart review was performed in 9 centres (n = 176, randomly selected patients) in Belgium (n = 56), France (n = 41), UK (n = 40) and Germany (n = 39). Costs were calculated from the payer's perspective by multiplying resource utilization with local unit costs from official sources. Data collection covered the 2-year period (or up to death) following treatment initiation in 2001. Descriptive statistics were performed on costs. Cost drivers were identified using a linear mixed regression model.
RESULTS:
The sample included 49% PD, 41% RCD and 10% RFD. Stem-cell or bone marrow transplantation rate was 52%. For PD, RCD and RFD respectively, 2-year costs were €59,648, €47,039 and €46,362, of which approximately 80% incurred during the first year. Transplantation rates differed between countries (39%-73%) and disease phase (68%, 40% and 28% in PD, RCD and RFD). Descriptive cost analysis showed potential impact of phase, survival, transplantation and centre. The regression model suggested costs to increase with number of transplantations (p < 0.0001), increasing stage at diagnosis (p = 0.0097), occurrence of complications (p = 0.0194) and decreasing age (p = 0.0004). The mean total cost was €31,612 (€26,300-€34,300) in patients without transplantation compared to €59,915 (€53,000-€66,600) in the transplant population. CONCLUSION: The study provided insight into cost drivers in MM. The main therapeutic cost driver was transplantation. Important centre-specific variation exists in transplantation accessibility. In addition, there is a lack of consensus on transplantation practices. Since the current study was undersized to represent national transplantation rates, further research is needed to establish real life transplantation rates in different MM settings. A cost of illness model estimated the annual cost of managing OAB in Germany, Italy, Spain, Sweden and the UK by defining a locally relevant package of care and multiplying resources used by country-specific unit cost data. The total cost of OAB in males was calculated by multiplying the estimated prevalence of OAB in males by the estimated annual direct cost of OAB management. The model also estimated the likely economic impact of increasing numbers of elderly men. RESULTS: The prevalence of OAB is known to be highest in the elderly and is commonly perceived to affect mostly women. However, in this study, 9.6 m males aged >40 were esti-
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